Point72 Asset Management L.P. Has $8.15 Million Stock Position in enGene Holdings Inc. (NASDAQ:ENGN)

Point72 Asset Management L.P. lifted its holdings in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) by 84.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,224,797 shares of the company's stock after buying an additional 561,797 shares during the quarter. Point72 Asset Management L.P. owned approximately 2.77% of enGene worth $8,145,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Fcpm Iii Services B.V. lifted its position in shares of enGene by 11.0% in the 4th quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company's stock worth $64,057,000 after buying an additional 954,610 shares during the last quarter. Deep Track Capital LP lifted its position in shares of enGene by 74.8% in the 4th quarter. Deep Track Capital LP now owns 4,557,575 shares of the company's stock worth $30,308,000 after buying an additional 1,949,942 shares during the last quarter. Blue Owl Capital Holdings LP lifted its position in shares of enGene by 3.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company's stock worth $21,014,000 after buying an additional 101,006 shares during the last quarter. Orbimed Advisors LLC bought a new position in shares of enGene in the 4th quarter worth about $6,120,000. Finally, Corton Capital Inc. bought a new position in shares of enGene in the 4th quarter worth about $157,000. 64.16% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on ENGN shares. JMP Securities reiterated a "market outperform" rating and issued a $18.00 price objective on shares of enGene in a research report on Tuesday, April 29th. UBS Group downgraded shares of enGene from a "buy" rating to a "neutral" rating and cut their price objective for the company from $34.00 to $7.00 in a research report on Friday, February 14th. Morgan Stanley cut their price objective on shares of enGene from $37.00 to $34.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 11th. HC Wainwright reiterated a "buy" rating and issued a $25.00 price objective on shares of enGene in a research report on Tuesday, March 11th. Finally, Piper Sandler began coverage on shares of enGene in a research report on Tuesday, February 18th. They issued an "overweight" rating and a $26.00 price objective on the stock. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $23.29.

enGene Trading Down 1.2%

Shares of enGene stock traded down $0.05 during trading on Friday, hitting $4.24. The stock had a trading volume of 45,475 shares, compared to its average volume of 133,060. The stock has a 50 day simple moving average of $4.07 and a 200 day simple moving average of $5.92. The company has a market capitalization of $216.15 million, a PE ratio of -7.31 and a beta of -0.36. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. enGene Holdings Inc. has a 1 year low of $2.65 and a 1 year high of $12.80.

enGene Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.